Caldera (Qyuns) Deal History & Licensing Activity
Caldera (Qyuns) is a biotech. Over the past three years, Caldera (Qyuns) has been involved in 4 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (3 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Bispecific Antibodies
Focus Area
Option Deals
Caldera (Qyuns) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Caldera (Qyuns) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| WIN027 | Windward Bio | Antibodies | Unknown | license | Dec 15, 2025 |
| WIN027 | Qyuns Therapeutics | Other | Unknown | license | Dec 15, 2025 |
| QX031N | Roche | Bispecific Antibodies | Phase 1 | license | Oct 30, 2025 |
Caldera (Qyuns) Pipeline Focus
Therapeutic areas and modalities where Caldera (Qyuns) is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Caldera (Qyuns)'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Option Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Caldera (Qyuns) Licensing & Deal Activity
Caldera (Qyuns) is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Caldera (Qyuns) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Caldera (Qyuns) include Option Deals (4 deals and trials), Immunology (2 deals and trials), and Gastroenterology (1 deal and trial). In terms of modality, Caldera (Qyuns) has shown particular interest in bispecific antibodies, antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Caldera (Qyuns) and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Caldera (Qyuns)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.